Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00035048

Enrollment

540

Registered

2002-05-03

Start date

2001-11-21

Completion date

2003-12-31

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Detailed description

The duration of treatment is 10 weeks.

Interventions

DRUGaprepitant

DRUGComparator: placebo (unspecified)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability	After 10 weeks & 6-10 months

Secondary

Measure	Time frame
CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6	6 Months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026